EMA committee recommends approval for injectable version of Merck's Keytruda

Core Viewpoint - The European Medicines Agency's committee has recommended the approval of a new formulation of Merck's cancer therapy Keytruda, which can be administered subcutaneously, potentially enhancing patient convenience and treatment adherence [1] Company Summary - Merck's Keytruda is a leading cancer therapy, and the new formulation aims to provide an alternative administration route that may improve patient experience [1] Industry Summary - The approval of subcutaneous formulations in cancer therapies reflects a growing trend in the pharmaceutical industry to enhance drug delivery methods, which could lead to increased market competitiveness and patient accessibility [1]